FLT3 inhibitors in acute myeloid leukaemia: assessment of clinical effectiveness, adverse events and future research—a systematic review and meta-analysis

BACKGROUND: FMS-like tyrosine kinase 3 (FLT3) is the most frequent mutation in AML. With two FLT3 inhibitors recently approved by the FDA (midostaurin and gilteritinib), there is a need to evaluate these targeted agents. PURPOSE: To assess the clinical effectiveness of FLT3 inhibitors in AML patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Majothi, S., Adams, D., Loke, J., Stevens, S. P., Wheatley, K., Wilson, J. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722339/
https://www.ncbi.nlm.nih.gov/pubmed/33287892
http://dx.doi.org/10.1186/s13643-020-01540-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7722339/
https://www.ncbi.nlm.nih.gov/pubmed/33287892
http://dx.doi.org/10.1186/s13643-020-01540-1

Ejemplares similares